{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
alpha-tocopherol
to a specific field?
Status:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dimetamfetamine is the N-methylated analog of methamphetamine, produces behavioral effects that are generally comparable to those of methamphetamine, but with reduced potency. It is often found as an impurity in preparations of methamphetamine. Dimetamfetamine itself is less neurotoxic than methamphetamine. Dimetamfetamine is metabolized to p-hydroxyl methamphetamine, p-hydroxyl dimetamfetamine, amphetamine, methamphetamine, and N,N-dimethylamphetamine N-oxide in humans, and flavin-containing monooxygenase-1 and CYP2D6 are mainly involved in the N-oxidation and N-demethylation of dimetamfetamine, respectively. Dimetamfetamine has also been used illegally in Korea, and the Korean government placed DMA on the official list of controlled substances on December 4, 2006.
Status:
Investigational
Source:
NCT01019824: Phase 3 Interventional Completed Pain
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Priralfinamide, also known as Ralfinamide, FCE-26742A; NW-1029; PNU-0154339E, is a Na-channel blocker for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), N-type calcium channel blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor. Priralfinamide is in phase Ⅲ clinical trials by Newron for the treatment of chronic neuropathic pain.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.
Status:
Investigational
Source:
NCT03467100: Phase 1 Interventional Completed Healthy Volunteers
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00625664: Phase 3 Interventional Completed Urinary Bladder Neoplasms
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Halocortolone, a synthetic glucocorticoid that was used as a vasoconstrictor, but was never marketed
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Azepexole (or previously known as B-HT 933), a selective alpha 2-adrenoceptor agonist that was studied for the man with physiological tremor. It was shown that the drug produced sedation compared to placebo but not when compared to pre-treatment values. Some studies also have revealed the anti-tussive and antihypertensive properties of azepexole.
Status:
Investigational
Source:
NCT01631487: Phase 1 Interventional Completed Healthy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Mavatrep (JNJ-39439335) is a TRPV1 antagonist. It exerts analgesic potential. Mavatrep demonstrated sustained pharmacodynamic effects (heat pain perception, heat pain latency, capsaicin-induced flare), and an efficacy signal in participants with osteoarthritis
Status:
Investigational
Source:
NCT04135495: Phase 2 Interventional Completed Cystic Fibrosis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Taprizosin (also known as UK-338,003) is an alpha1A-adrenoceptor antagonist that was developed for the treatment of benign prostatic hyperplasia. However, this compound possesses poor oral absorption.
